A lymphotropic hepatitis C virus strain (HCV, SB strain, hereafter "SB-HCV") has been shown to infect established T cell lines (Molt-4 and Jurkat) and primary human naive CD4 ϩ T cells. During T cell development and activation, transient expression of CD44 splicing variant 6 (CD44v6) plays a significant role.
Hepatitis C virus (HCV) infects about 170 million people worldwide and is a major cause of chronic hepatitis, cirrhosis, and hepatocellular carcinoma (HCC) [1] . HCV infection is often persistent and cellular immune response to HCV plays an important role in the pathogenesis of chronic hepatitis, cirrhosis, and HCC [2] . Several mechanisms have been proposed for the failure of HCV-specific CD4 ϩ and CD8 ϩ T cell response during HCV infection; these include deletion, anergy, cytotoxic T lymphocyte exhaustion, and suppression via regulatory CD4 ϩ CD25 ϩ T cells and interleukin-10 (IL-10)-secreting regulatory CD8 ϩ T cells [3, 4] .
Previously we have shown that a strain of HCV (strain SB, hereafter "SB-HCV") can infect and replicate in not only B cells but also T cells as well, and that HCV replication in T cells can inhibit signaling by interferon-␥, signal transducer and activator of transcription factor 1 (STAT-1), and T-bet signaling of T cells [5] . However, the replication activity of SB-HCV in T cells is weaker than that in B cells, suggesting that the lymphotropic SB-HCV might preferentially replicate in B cells but nevertheless affect T cell development in local lymph nodes. In particular, among CD4 ϩ cells, CD45RA
ϩ -CD45RO Ϫ CD4 ϩ cells are the most susceptible to HCV infection [5] . It is known that during the activation that shifts T cells from naive to effector cells, T cells have to survive activation-induced cell death (AICD), which may contribute to the maintenance of an appropriate level of immune response. Fas-Fas ligand signaling is thought to be one of the mechanisms of AICD [6, 7] . There are several splicing variants of the immune molecules in T cells that contribute to proper immune response [8] . We have reported that SB-HCV could replicate in T cells during different temporal periods [5] . Therefore, we focused on CD44 splicing variants because the temporal regulation of alternative CD44 splicing in T lymphocytes plays a significant role in the maintenance of appropriate T cell development [8] . The CD44 family of transmembrane glycoproteins is present on a wide variety of cell types, including lymphocytes, neutrophils, endothelial cells, and fibroblasts [9, 10] . CD44 molecules display a multitude of functions involving a large array of signal transduction pathways, and CD44 is expressed into multiple splicing variants [11, 12] . During T cell development and activation, transient expression of CD44 splicing variant 6 (CD44v6) plays a significant role [13, 14] . The expression of CD44v6 provides a proliferative stimulus for T cells independent of the T cell receptor (TCR)-CD3 complex. Proliferative activity is accompanied by activation of the mitogen-activated protein kinase (MAPK) pathway [15] . Moreover, CD44v6 expression could interfere with Fas signaling [16] .
Recently, the roles of individual HCV proteins have been studied extensively by using HCV-producing hepatocyte cell lines and the replicon system [17] [18] [19] [20] [21] . The processing of the HCV precursor polyprotein requires both host and viral proteases to produce structural and nonstructural proteins. Among the nonstructural proteins, NS5A interacts with a number of cellular proteins and may interfere with host cell signaling pathways [22, 23] . Several authors have reported that NS5A can inhibit the extracellular signal-regulated kinase (ERK)-MAPK pathway; however, several other HCV proteins, such as HCV core protein, have been reported to enhance this pathway [24, 25] . The mechanism of CD44v6 inclusion is still not clear, although it is known that the events upstream of this inclusion mechanism may include Ras-ERK activation [8, 26, 27] . Thus, HCV replication in T cells may affect proliferation and Fasmediated apoptosis of T cells by altering CD44v6 expression or MAPK activation. During T cell development, T cells undergo vigorous proliferative activity which might facilitate HCV replication in T cells. However, extensive proliferation of HCV in T cells might interfere with proper T cell development.
Previously, our reports have indicated that SB-HCV, which was produced from an HCV-positive B-cell lymphoma cell line (SB cells), can infect and replicate in established B cell lines (Raji and Daudi), established T cell lines (Molt-4 and Jurkat), and primary lymphocytes [5, 28, 29] . HCV infection of these immune cells conceivably can perturb their functions. This study was conducted to analyze whether HCV replication in T lymphocytes might affect the proliferative activity and apoptosis of T cells as a result of signaling changes and aberrant expression of CD44 variants.
MATERIALS AND METHODS
Culture of cell lines. SB cells, which continuously produce infectious HCV particles, were originally cultured from splenocytes obtained from an HCV-infected patient with type 2 mixed cryoglobulinemia and monocytoid B-cell lymphoma [29] . The cells were maintained in standard RPMI 1640 (Invitrogen) medium that contained 20% fetal bovine serum (FBS) without any supplement. Huh7.5 cells, which were kindly provided by C.M. Rice (Laboratory of Virology and Infectious Disease, Center for the Study of Hepatitis C, The Rockefeller University), were cultured at 37°C in Dulbecco's modified Eagle medium containing 10% FBS.
In vitro infection of Molt-4 and primary naive (CD45RA ؉ -CD45RO ؊ ) CD4
؉ cells. SB cell culture supernatant (5 mL), which contained 2.2 ϫ 10 4 copies/mL of HCV RNA, was used to infect Molt-4 and human naive CD4 ϩ cells (1 ϫ 10 5 cells). Control cells infected with UV-irradiated SB cell culture supernatant (hereafter, "UV-SB-HCV-infected cells") were included in every experiment. Supernatant from Huh7.5 cells transfected with JFH-1 strains [19, 20, 30] at 10 days after transfection were used for several control experiments. Cells were washed 3 times at 5 days after infection. A portion of the cells (3 ϫ 10 5 -5 ϫ 10 5 cells) was then harvested for analysis; the remaining cells (1 ϫ 10 5 cells) were kept and incubated further.
Strand-specific intracellular SB-HCV RNA detection and quantitative SB-HCV RNA detection in the culture supernatant. Strand-specific intracellular SB-HCV RNA was detected by using a recently established procedure that combined methods published elsewhere [31, 32] , with minor modifications [5] . Positive strand-specific and negative strand-specific SB-HCV RNA were detected by use of a nested polymerase chain reaction (PCR) method.
To quantify SB-HCV RNA in the culture supernatant, SB-HCV RNA extraction from culture supernatant (140 L) was carried out with QIAmp Viral RNA Minikit (Qiagen). Amplification was performed in 20-L reaction mixtures that contained AmpliTaq Gold DNA polymerase and optimized buffer (TaqMan Universal PCR Master Mix; Applied Biosystems) with the ABI prism 7900 sequence detector system. Forward primer (300 nmol/L), nucleotide 215-197, (5'-TCCCGGGAGAGCCATAG-TG-3'); reverse primer (600 nmol/L), nucleotide 158 -140, (5'-TCCAAGAAAGGACCCRGT-3'); and 250 nmol/L TaqMan minor-groove-binding (MGB) probe labeled with 6-carboxyfluorescein, nucleotide 195-181, (5'-FAM-TCTGCGGAACC-GGTG-MGB-3') were also included in the PCR mix reaction. In vitro-transcribed full-length HCV RNA was used as a standard.
Analysis of standard CD44 (CD44s) mRNA and variant mRNA. Cells were collected sequentially at various time points after addition of phorbol myristate acetate (PMA) or anti-CD3 antibody. After extraction of total RNA and a reverse-transcriptase procedure, real-time PCR and semiquantitative PCR were carried out. Real-time PCR analysis was performed in accordance with methods described elsewhere, with minor modifications [33, 34] . Forward primer for CD44s (5'-CAACTCCATCTGTGCAGCAAA-3'), CD44v3 (5'-GCAGGCTGGGAGCCAAAT-3'), and CD44v6 (5'-GCAACTCCTAGTAGTAC AACGGAAGA-3'); reverse primer for CD44s (5'-CAACTCCATCTGTGCAGCAAA-3'), CD44v3 (5'-TCATCAATGCCTGATCCAGAAA-3'), and CD44v6 (5'-CGATATCCCTCATGCCATCTGA-3'); and probe for CD44s (5'-FAM-CATATTGCTTCAATGCTTCAGCTCCACCTC-TAMRA-3'), CD44v3 (5'-FAM-AGGTGTCTGTCT-CTTTCATCTTCAT-TAMRA-3'), and CD44v6 (5'-FAM-ACAG-CTACCCAGAAGGAACAGTGGTTTGG-TAMRA-3') were used for analysis. Semiquantified analysis was carried out by use of primers and cycles described elsewhere [27] .
Staining of surface CD44s and variants. The surface expression of CD44s and the variants was analyzed by immunofluorescence labeling. Nonspecific binding was blocked by using PBS containing 1% bovine serum albumin. Cells were incubated for 15 min with the primary antibody. Monoclonal anti-CD44s, anti-CD44v3, and anti-CD44v6 antibodies were all obtained from R&D Systems. Murine IgG2b, IgG2a, and IgG1 were applied as isotype controls. Cells were washed 3 times in PBS, then incubated for 15 min with fluorescein isothiocyanate (FITC)-or allophycocyanin (APC)-conjugated goat anti-mouse IgG, followed by washing 3 times in PBS. Fluorescence was measured by use of a flow cytometer (FACSCalibur; Becton Dickinson).
Carboxyfluorescein succinimidyl ester (CFSE) staining and sorting. Cells were analyzed with the CellTrace CFSE Cell Proliferation Kit (Molecular Probes). CFSE staining was carried out at 5 days after infection; the cell staining methods used were in accordance with the manufacturer's protocol. Stained cells were washed 3 times and incubated for an additional 10 days because our previous study showed that active HCV replication in T cells occurred during this period [5] . Cells were analyzed by use of flow cytometry with 488-nm excitation and emission filters.
Immunoblotting analysis: MAPK signaling, Fas signaling, and immunoprecipitation (Western blot). Proteins were resolved by electrophoresis in sodium dodecyl sulfate-polyacrylamide gels and electrophoretically transferred onto nitrocellulose membranes (Amersham Biosciences). The membrane was incubated with anti-P44/42 MAP kinase, anti-phospho-P44/42 MAP kinase, anti-MAPK/ERK kinase (MEK) 1/2, antiphospho-MEK 1/2, anti-phospho-cRaf, anti-caspase 8, or anti-caspase 3 antibodies (Cell Signaling) and then subjected to reaction with peroxidase-conjugated secondary antibody. Immunoreactivity was visualized with enhanced-chemiluminescence detection (Amersham Biosciences).
Annexin V and propidium iodide (PI) staining. Cells were stained with annexin V antibody and PI by use of an apoptosis detection kit (R&D systems). The staining methods used were in accordance with the manufacturer's protocol.
Transfection of HCV individual protein expression plasmids. The various expression plasmids were constructed by inserting HCV core protein, E1, E2, NS3, NS4B, NS5A, and NS5B cDNA of genotype 1a [35] behind the cytomegalovirus virus immediate-early promoter in pCDNA3.1 (Invitrogen). Molt-4 cells were transfected by use of the Gene Pulser II (BioRad), and various plasmids were purified by using the EndFree plasmid kit (QIAGEN). Viable transfected cells were isolated by Ficoll-Paque centrifugation (Amersham Biosciences) at 24 h after transfection.
Confocal laser microscopy. Molt-4 cells (3 ϫ 10 6 cells/mL) in suspension were fixed and permeabilized with Fixation/Permeabilization solution (BD Biosciences) at 4°C for 25 min. The cells were then washed 2 times in BD Perm/Wash buffer (BD Biosciences) and resuspended in 50 L of BD Perm/Wash buffer containing preconjugated polyclonal anti-NS5A antibody (Biodesign International) with an FITC-conjugated anti-mouse antibody.
Isolation of naive CD4 ؉ T cells and culture conditions. 
RESULTS

Suppression of CD44v6 mRNA, but not CD44s or CD44v3-mRNA, and its surface protein expression in SB-HCV-infected
Molt-4 cells. Our group has previously reported that SB-HCV [29] can infect and replicate in established B cell lines (Raji and Daudi), T cell lines (Molt-4 and Jurkat), and primary lymphocytes [5] . We also reported that SB-HCV infection can affect the signaling and biological functions of B cells [28, 36, 37] . We then proceeded to study whether SB-HCV infection could affect the functions of T cells. We first examined the expression of splicing variants CD44v3 and CD44v6, the latter of which is regarded as an important factor for T cell development and activation since Molt-4 cells can be used for the analysis of CD44v3 and CD44v6 after PMA stimulation. All the splicing variants of CD44 have previously been shown to be up-regulated by PMA stimulation, which mimics TCR stimulation [38] .
We first analyzed the time course of CD44s, CD44v3, and CD44v6 mRNA up-regulation in Molt-4 cells after PMA stimulation. We found that the expression of mRNA by these isoforms peaked at 8 -12 h after stimulation, whereas the maximum upregulation of surface expression of these CD44 variants was observed at 24 h after stimulation (data not shown). Therefore, to determine whether HCV could affect the expression of different splicing variants of CD44, we compared the expression level of these variants in cells that had been mock-infected, infected with UV-SB-HCV, or infected with SB-HCV; this comparison was performed at 8 h after activation for mRNA analysis and 24 h after activation for surface protein analysis. The status of HCV infection and replication was confirmed by detecting negativestrand HCV RNA by semiquantitative reverse-transcriptase PCR (figure 4, which appears only in the electronic version of the Journal, and summarized in figure 1B) .
All the CD44 variants examined showed a low level of mRNA expression, which was significantly increased after PMA stimulation (figure 1). We noted that CD44v6 mRNA expression in SB-HCV-infected Molt-4 cells was slightly but significantly lower than that observed in control groups, even without PMA stimulation (P Ͻ .05), and this difference became more prominent after PMA stimulation (P Ͻ .001) (figure 1). In contrast, the mRNA expression of CD44s and CD44v3 was not affected by HCV infection status. We further confirmed the suppression of CD44v6 mRNA by HCV infection in primary naive T cells (figure 1B) . In this case, the primary CD4 ϩ cells were stimulated with anti-CD3 antibody, and the suppression of CD44v6 mRNA became more apparent after stimulation. Taken together, these data indicate that HCV replication in CD4 ϩ cells specifically suppressed CD44v6 mRNA inclusion.
To corroborate this finding, we then analyzed surface expression of CD44s, CD44v3, and CD44v6 among the 3 groups of cells (mock infected, UV-SB-HCV infected, and SB-HCV infected) (figure 2). The mean fluorescence intensity (MFI) of CD44v6 with or without PMA stimulation was significantly suppressed in SB-HCV-infected Molt-4 cells, compared with Molt-4 cells that had been mock infected or infected with UV-SB-HCV (P Ͻ .01) (figure 2A). CD44s and CD44v3 also showed slightly lower levels of expression after PMA stimulation in HCVinfected cells; however, these differences were not statistically significant. The lower surface expression of CD44v6 in SB-HCV-infected cells was further confirmed by fluorescenceactivated cell sorter analysis (figure 2B). These data suggested that SB-HCV infection of T cells caused down-regulation of CD44v6 and that HCV replication in T cells, not merely the binding of HCV to T cells, is required for this effect.
To further demonstrate that HCV replication was required for the down-regulation of CD44v6 expression in T cells, we used JFH-1 HCV [20] to infect Molt-4 cells. We have previously shown that JFH-1-HCV cannot infect or replicate in lymphocytes (Machida et al., unpublished data). Molt-4 cells infected with JFH-1 HCV and Molt-4 cells infected with UV-irradiated JFH-1 HCV showed no difference in mRNA or surface protein expression for CD44s, CD44v3, or CD44v6 (data not shown). Therefore, HCV replication might be necessary for the down-regulation of CD44v6 inclusion in T cells. However, we could not rule out the possibility that SB-HCV has a unique ability to down-regulate CD44v6 inclusion because we have so far only been able to use the SB strain to infect T cells.
SB-HCV infection of T cells and decreased proliferation.
Since CD44v6 expression is associated with cellular proliferation, we analyzed the proliferative activity of SB-HCV-infected Molt-4 cells [15] . The results showed that SB-HCV-infected Molt-4 cells could be clearly separated into 2 groups (CFSE high figure 5A ). The CFSE-high and CFSE-low groups were separated and analyzed for NS5A expression. The data showed that 82.4% of the CFSE-high group expressed NS5A protein, whereas only 1.2% of the CFSE-low group were positive for NS5A (figure 5B). These data indicated that most cells in the CFSE-high group (i.e., the slow-growing group) were infected with SB-HCV, whereas the uninfected cells were mostly fast growing. Therefore, SB-HCV infection suppressed the proliferation activity of Molt-4 cells.
SB-HCV infection and suppression of Ras-MEK-ERK activation and CD44v6 up-regulation in T cells.
We next analyzed the Ras-MEK-ERK signaling that may induce proliferation-related genes, since it has been reported that this signaling is the upstream mechanism of CD44 variant inclusion and that CD44v6 can enhance this signaling, acting like a positive loop [27] . The CFSE-high group (i.e., the enriched SB-HCV-infected Molt-4 cells) showed significantly lower levels of phospho-cRaf, phospho-MEK, and phospho-ERK after PMA stimulation than did cells in the control groups (mock-infected cells, cells infected with UV-SB-HCV, and cells in the CFSE-low group) ( figure 5C ). These data indicated that HCV replication in T cells suppressed the PMAinduced activation of Ras-MEK-ERK signaling. Three independent experiments yielded similar results. FSC, forward scatter characteristics; P-cRaf, phospho-cRaf; P-ERK, phospho-ERK; P-MEK, phospho-MEK.
We next carried out double staining analysis of CD44 variants and CFSE to further confirm the correlation between low CD44v6 expression and high CFSE staining. The result showed that the CFSE-high group (the cells infected with SB-HCV) had a significantly lower level of CD44v6 expression than did the cells in the CFSE-low group (P Ͻ .01) (figure 6A). CD44s and CD44v3 were only weakly suppressed in the SB-HCV-infected CFSE-high cells, compared with the CFSElow group (figure 6B).
SB-HCV infection and enhanced Fas-dependent apoptosis by suppression of CD44v6. We next analyzed Fas-mediated apoptosis because CD44v6 has been reported to cause suppression of Fas-mediated apoptosis [16] . Immunoblotting analysis showed that, after treatment with Fas ligand (FasL), Molt-4 cells infected with SB-HCV had a higher extent of cleavage of caspases 8 and 3 than did cells that had been mock infected or infected with UV-SB-HCV (figure 7A), whereas the surface expression levels of Fas and FasL were almost the same among the 3 groups ( figure 7B) . Moreover, pretreatment of cells with anti-CD44v6 antibody that could block the interaction of CD44v6 with Fas [15] eliminated the differences in caspase activation among the 3 groups ( figure 7A ). The number of early apoptotic cells, which were represented as annexin V-positive, PI-negative cells, was significantly increased among the SB-HCV-infected Molt-4 cells after Fas stimulation (the percentage of early apoptotic cells in each group was as follows: mock infected, 29.8%; UV-SB-HCV infected cells, 29.6%; and SB-HCV infected cells, 41.3%) (figure 7C). These results indicated that SB-HCV infection caused suppression of the CD44v6 isoform, leading to the enhancement of Fas-mediated apoptosis.
NS5A protein and suppression of CD44v6 in T cells. To determine which viral protein was responsible for CD44v6 suppression, we expressed each HCV protein in Molt-4 cells and then studied its effects on CD44v6 expression. The transfection efficiency of each plasmid was ϳ50%, and cell viability after transfection was Ͼ80% after purification by Ficoll-Paque centrifugation. The results showed that, among all the viral proteins, only NS5A could suppress CD44v6 significantly (P Ͻ .01) ( figure 3A) . The NS5A-induced CD44v6 suppression was particularly evident after PMA stimulation. Immunoprecipitation by Western blot analysis showed that CD44v6 could coprecipitate with Fas, and the amount of CD44v6-associated Fas was reduced in NS5A-expressing Molt-4 cells, compared with Molt-4 cells without NS5A (figure 3B). As a control, STAT-1 antibody did not coprecipitate CD44v6. 
DISCUSSION
The SB cell line, which was derived from an HCV-positive B-cell lymphoma, produces lymphotropic HCV particles that can infect and replicate in B cell lines, such as Raji and Daudi cells, as well as PBMCs [28, 29] . Most recently, we also demonstrated that SB-HCV could infect T cell lines, such as Molt-4 cells, and that this system could be used for signaling analysis of T cells [5] . Although there has been accumulating evidence indicating that HCV could replicate in both established T cell lines and primary T lymphocytes, so far little is known about the extent and biological significance of T cell infection [39 -41] . The site of infec- tion, as well as proliferative activity and the subset of CD4 ϩ cells involved may be important factors for HCV replication in vivo [42] . Some authors have suggested that coinfection with human T cell lymphotropic virus type 1 or HIV might induce HCV replication in T lymphocytes [43] [44] [45] . Previously, our data indicated that with CD3 and IL-2 stimulation, naive CD4 ϩ T cells could be one of the target cells for HCV [5] . As a result of HCV infection, changes in the development and activation of apoptosis-related molecules in T cells may contribute partially to T cell hyporesponsiveness in some patients with hepatitis C. The temporal expression of CD44v6 is important for proliferation, activation, and apoptosis in T cells [13, 16] . The suppression of CD44v6 expression or Ras-MEK-ERK signaling by HCV replication disrupted the positive loop of proliferation in T cells [27] . We could not conclude that CD44v6 suppression was either the result or the cause of Ras-MEK-ERK suppression, since Ras-MEK-ERK have been reported as upstream regulatory molecules for CD44v6 expression and CD44v6 could enhance Ras-MEK-ERK suppression [27] . However, unexpectedly, the other CD44 splicing variants, for example CD44v3, could not be suppressed by Ras-MEK-ERK signaling in this Molt-4 cell infection system [13, 14] . Our studies further showed that the protein NS5A is responsible for CD44v6 suppression. One of the possible mechanisms for this suppression is the stimulation of phosphatase 2A activity that can suppress MAPK signaling [24] . However, many individual HCV proteins have been reported to affect MAPK signaling and apoptotic signaling in diverse ways [25] ; our Molt-4 cell HCV replication system showed that HCV replication, and NS5A protein alone, could suppress CD44v6 expression and MAPK signaling in T cells. Moreover, the results of Fas signaling experiments showed that suppression of CD44v6 might contribute to the apoptosis of T cells. However, some authors have reported that NS5A can inhibit apoptosis in hepatoma cell lines [46, 47] . One of the explanations for these contradictory results probably lies in the developmental stages and characteristics of the naive T cells. During T cell activation, apoptosis is easily induced, in order to maintain an appropriate immune response. During this stage, suppression of CD44v6 might strongly affect apoptosis signaling in T cells.
We have found that our results apply not only to T cell lines, but also to primary naive T cells. We could also detect significant suppression of proliferation after SB-HCV infection (data not shown). Furthermore, in our ongoing clinical study some clinical samples (PBMCs) from patients with chronic hepatitis C showed a significant, albeit small, degree of CD44v6 downregulation with CD3 stimulation (data not shown).
We conclude that HCV replication in T cells may play a role in the regulation of proliferation and apoptosis during T cell acti- 
